Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
Healthcare
$2.73 +1.06%
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
52W Low $4.00High $7.54
Volume 1.71M
Average 1.12M
Income Statement
Follow revenue through to earnings.
Revenue
$5.82M
FY 2025 · Annual
Operating Income
-$89.45M
FY 2025 · Annual
Net Income
$71.18M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3M | 1.41M | 3.5M | 0 | 5.82M |
| Cost of Revenue | 0 | 450K | 1.61M | 2.91M | 1.53M |
| Gross Profit | 3M | 964K | 1.9M | (2.91M) | 4.29M |
| Gross Margin | 100.0% | 68.2% | 54.1% | — | 73.7% |
| Research & Development | 38.73M | 28.97M | 31.09M | 34.36M | 26.81M |
| Selling, General & Admin | 21.64M | 17.26M | 19M | 29.85M | 65.03M |
| Operating Expenses | 92.84M | 51.88M | 49.03M | 61.3M | 93.74M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| EBITDA | (76.82M) | (34.38M) | (50.57M) | (56.62M) | 78.59M |
| EBITDA Margin | -2560.5% | -2431.6% | -1444.9% | — | 1350.3% |
| Operating Income | (89.84M) | (50.92M) | (47.14M) | (64.21M) | (89.45M) |
| Operating Margin | -2994.5% | -3600.8% | -1346.7% | — | -1536.9% |
| Interest Income | 40K | 431K | 2.12M | 4.25M | 5.56M |
| Interest Expense | 3.66M | 736K | 418K | 4.21M | 3.74M |
| Other Income / Expenses | 4.9M | 11.22M | (7.05M) | 477K | 160.73M |
| Income Before Tax | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.28M |
| Pre-Tax Margin | -2831.2% | -2807.4% | -1548.2% | — | 1224.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 100K |
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Net Margin | -2831.2% | -2807.4% | -1548.2% | — | 1223.1% |
| EPS (Basic) | (21.50) | (5.53) | (2.53) | (1.55) | 1.34 |
| EPS (Diluted) | (21.50) | (5.53) | (2.53) | (1.55) | 1.01 |
| 3.94M | 7.86M | 21.38M | 41.05M | 52.95M | |
| 3.94M | 7.86M | 21.38M | 41.05M | 66.14M |
ABEO Earnings Waterfall · TTM
NASDAQ:ABEO · Revenue to Net Income
Key Ratios
EPS$0.95
Gross Margin45.4%
Net Margin6658.7%
P/E Ratio-5.1
P/S Ratio206.6
Analysis
$14.5M of revenue converted into $66.1M of net income for the selected period. Gross margin is 45.4% and net margin is 6658.7%, showing how much revenue survives after costs and taxes. EPS is $0.95, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 |
How much revenue does ABEO generate?
Abeona Therapeutics Inc. (ABEO) reported $5.82M of revenue in fiscal 2025.
Is ABEO profitable?
Abeona Therapeutics Inc. (ABEO) reported $71.18M of net income, with a net margin of 1223.1%.
Continue the stock analysis
Jump to another research area for this company.